HRTX — Heron Therapeutics, Inc.
Is HRTX overbought or oversold? Here is the current MarketMoodz read.
Heron Therapeutics, Inc. (HRTX) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.28. The rating moved from Neutral to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$0.28
- Last changeMoved from Neutral to Strong Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Heron Therapeutics, Inc. (HRTX) exhibits characteristics of a distressed small-cap biotech with a very low share price, limited liquidity, and likely short cash runway absent near-term financing or asset monetization. Sector momentum favors large-cap, defensive healthcare names and there is little visible near-term catalyst to reverse sentiment; convertible-debt and dilution risk are meaningful. Potential upside would require positive clinical readouts, partnership/M&A interest, or a financing that meaningfully de-risks the balance sheet; absent such events, downside remains the higher-probability outcome.
Key factors
- Severely depressed share price and implied market capitalization reflecting material market skepticism and likely limited liquidity
- Weak financial position typical of small-cap biotechs: probable cash burn, limited near-term revenue, and need for external financing or asset transactions
- Lack of visible, near-term commercial drivers or late-stage trial readouts to materially re-rate the stock
- Sector dynamics favor large-cap pharma and defensive healthcare, reducing investor appetite for speculative microcap biotech exposure
- Convertible-debt and financing pressures across mid-cap biotech increase dilution risk for equity holders
- Low social and analyst coverage reduces positive sentiment catalysts and market support
Risks
- Near-term dilution through equity financings or convertible debt to fund operations, depressing shares
- Failure of any clinical programs or inability to secure partnerships/licensing deals
- Trading illiquidity leading to sharp price jumps on thin order flow or block sales
- Regulatory setbacks, manufacturing or commercial execution failures if any product assets progress
- Downside from broader risk-off swings in small-cap biotech or a reversal of the limited market optimism
- Potential bankruptcy or distressed restructuring if cash runway is insufficient and financing options are exhausted
See today's live rating, score and targets
Members see the live hourly rating for HRTX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.